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of positron emission tomography (PET) in normal, overweight, and obese patients.
BACKGROUND Cardiac rubidium82 (Rb-82) PET is increasingly being used formyocardial perfusion im-
aging (MPI). A strength of PET is its accurate attenuation correction, thereby potentially improving its diag-
nostic accuracy in obese patients. The prognostic value of PET in obese patients has not been well studied.
METHODS A total of 7,061 patients who had undergone Rb-82 PET MPI were entered into a multi-
center observational registry. All patients underwent pharmacologic Rb-82 PET and were followed for
cardiac death and all-cause mortality. Based on body mass index (BMI), patients were categorized as
normal (<25 kg/m2), overweight (25 to 29.9 kg/m2), or obese ($30 kg/m2). Using a 17-segment model
and 5-point scoring system, the percentage of abnormal myocardium was calculated for stress and rest
patients categorized as normal (0%), mild (0.1% to 9.9%), moderate (10% to 19.9%), and severe ($20%).
RESULTS A total of 6,037 patients were followed for cardiac death (median: 2.2 years) and the mean
BMI was 30.5  7.4 kg/m2. A total of 169 cardiac deaths were observed. PET MPI demonstrated indepen-
dent and incremental prognostic value over BMI. Normal PET MPI conferred an excellent prognosis with
very low annual cardiac death rates in normal (0.38%), overweight (0.43%), and obese (0.15%) patients.
As well, both moderately and severe obese patients with a normal PET MPI had excellent prognosis
(0.20% and 0.10%, respectively). The net reclassiﬁcation improvement of PET was 0.46 (95% conﬁdence
interval [CI]: 0.31 to 0.61), and appeared similar in the moderately and severe obese patients which were
0.44 (95% CI: 0.12 to 0.76) and 0.63 (95% CI: 0.27 to 0.98), respectively.
CONCLUSIONS Rb-82 PET has incremental prognostic value in all patients irrespective of BMI.
In the obese population, where other modalities may have reduced diagnostic accuracy, cardiac
PET appears to be a promising noninvasive modality with prognostic value. (J Am Coll Cardiol Img
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279besity is a growing pandemic in both
developed and developing countries (1).
Diagnosis and assessment of the severity
of coronary artery disease (CAD) in obese
patients are important for reducing mortality and
morbidity. Investigating obese patients for CAD
continues to be a challenge because the diagnostic
accuracy of noninvasive imaging is often limited by
poor exercise tolerance, poor acoustic windows,
attenuation artifact, and/or poor signal-to-noise
ratios (2–4). Obese patients are also at higher risk of
complications from invasive investigations (5). Thus,
it is important to identify noninvasive modalities
that have preserved diagnostic and prognostic value
in patients irrespective of body mass index (BMI).See page 288
A B B R E V I A T I O N S
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AC = attenuation correction
BMI = body mass index
CAD = coronary artery disease
CI = conﬁdence interval(s)
CT = computed tomography
IQR = interquartile range
MI = myocardial infarction
MPI = myocardial perfusion
imaging
PET = positron emission
tomography
Rb-82 = rubidium Rb 82
SDS = summed difference score
SPECT = single-photon emission
computed tomography
SSS = summed stress scoreCardiac rubidium 82 (Rb-82) positron emission
tomography (PET) is increasing in clinical use for
the assessment of myocardial perfusion imaging
(MPI). Although it appears to have superior
diagnostic accuracy and lower patient radiation
exposure, its most recent rise in favor may have
been brought about by the recent technetium Tc
99m shortage. Some of the advantages of PET
(accurate scatter and attenuation correction) may
allow it to maintain diagnostic accuracy in the
obese population (6). Though PET has prognostic
value over routine clinical predictors for all-cause
mortality and major adverse cardiac events, its
prognostic value in obese patients has not been well
studied (7–9).
The objective of this large multicenter cohort
study is to understand whether the incremental
prognostic value of Rb-82 PET MPI is maintained
in normal, overweight, and obese patients.yyCardiovascular Research Methods Centre, University of Ottawa Heart In
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Study population. A total of 7,061 patients from
4 centers who had undergone Rb-82 PET MPI
were entered into a multicenter observational reg-
istry. All patients underwent pharmacologic Rb-82
PET as per their local clinical protocol (8) and
were followed for cardiac death and all-cause mor-
tality (7–11). The study was approved by each
center’s institutional human research ethics board.
At the time of PET, a medical history was
recorded for all patients (8). Based on BMI, patients
were categorized as normal (<25 kg/m2), over-
weight (25.0 to 29.9 kg/m2), or obese ($30 kg/m2).
Obese patients were further categorized as moder-
ately obese (30.0 to 34.9 kg/m2) and severely obese
($35 kg/m2).
PET image analysis. All patients refrained
from caffeine ingestion for $12 h prior to
MPI. Patients underwent pharmacologic
stress Rb-82 PET MPI using center-
speciﬁc protocols (7,9,12–14). Rb-82 was
infused intravenously and images were
acquired at rest and following pharmaco-
logic stress using center-speciﬁc imaging
and stress protocols. Rb-82 MPI was ac-
quired using a dedicated PET (ECAT
ART; Siemens-CTI, Knoxville, Tennes-
see; Posicam HZL/R, Positron Corpora-
tion, Houston, Texas) or a hybrid PET/
computed tomography (CT) scanner
(Discovery Rx or STE Light Speed [16,
64 slice CT], GE Healthcare, Milwaukee,
Wisconsin; Biograph 64, Siemen’s, Knox-
ville, Tennessee). Attenuation correction
was performed using a radionuclide line
source or using a low-dose chest CT scan.stitute, Ottawa, Ontario, Canada; and the zzDepartment of
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Table 1. Patient Characteristics of the Cardiac Death Cohort
All Patients
(n [ 6,037)
BMI <25.0 kg/m2
(n [ 1,303)
BMI 25.0–30.0 kg/m2
(n [ 2,047)
BMI ‡30.0 kg/m2
(n [ 2,687) p Value
Follow-up, per yr 2.23 (1.29–3.38) 2.21 (1.19–3.32) 2.47 (1.21–3.58) 2.37 (1.24–3.50)
Age, per yr 62.4  12.9 65.0  14.0 63.8  12.6 60.0  12.1 <0.001
Female 2,904 (48.1) 685 (52.6) 778 (38.0) 1,441 (53.6) <0.001
BMI, per
unit increase in kg/m2
30.5  7.4 22.3  2.2 27.4  1.4 36.8  6.3
Cardiac risk factors
Smoker/ex-smoker 1,435 (23.8) 340 (26.1) 484 (23.6) 611 (22.7) 0.065
Hypertension 4,004 (66.3) 732 (56.2) 1,286 (62.8) 1,986 (73.9) <0.001
Dyslipidemia 3,863 (64.0) 709 (54.4) 1,334 (65.2) 1,820 (67.7) <0.001
Diabetes 1,619 (26.8) 193 (14.8) 440 (21.5) 986 (36.7) <0.001
History of myocardial
infarction
1,230 (20.4) 254 (19.5) 441 (21.5) 535 (19.9) 0.259
History of CAD/
revascularization
1,597 (26.5) 344 (26.4) 597 (29.2) 656 (24.4) 0.001
Chest pain/dyspnea 3,778 (62.6) 738 (56.6) 1,266 (61.8) 1,774 (66.0) <0.001
LVEF, n ¼ 2,101 57.1  14.6 55.7  16.3 55.7  14.8 58.8  13.3 <0.001
SSS category <0.001
Normal 2,521 (41.8) 656 (50.3) 857 (41.9) 1,008 (37.5)
Mild 2,401 (39.8) 408 (31.3) 785 (38.3) 1,208 (45.0)
Moderate 561 (9.3) 120 (9.2) 184 (9.0) 257 (9.6)
Severe 554 (9.2) 119 (9.1) 221 (10.8) 214 (8.0)
SRS <0.001
Normal 3,287 (54.4) 826 (63.4) 1,133 (55.3) 1,328 (49.4)
Mild 2,240 (37.1) 362 (27.8) 724 (35.4) 1,154 (42.9)
Moderate 272 (4.5) 58 (4.5) 96 (4.7) 118 (4.4)
Severe 238 (3.9) 57 (4.4) 94 (4.6) 87 (3.2)
SDS <0.001
Normal 3,739 (61.9) 846 (64.9) 1,231 (60.1) 1,662 (61.9)
Mild 259 (4.3) 62 (4.8) 77 (3.8) 120 (4.5)
Moderate 1,831 (30.3) 358 (27.5) 654 (31.9) 819 (30.5)
Severe 208 (3.4) 37 (2.8) 85 (4.2) 86 (3.2)
Values are median (interquartile range), mean  SD, or n (%).
BMI ¼ body mass index; CAD ¼ coronary artery disease; LVEF ¼ left ventricular ejection fraction; SDS ¼ summed difference score; SRS ¼ summed rest score; SSS ¼ summed
stress score.
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280Using a 17-segment model and 5-point scoring
system (normal [0], mild [1], moderate [2], severe
[3], and absent [4] radiotracer uptake), summed
stress score (SSS), summed rest score, and summed
difference score (SDS) were calculated. At 3 sites,
the percentage (%) of myocardium was calculated
using summed scores divided by 68 and multiplied
by 100, and 1 site used software as described pre-
viously (15). Patients were categorized as normal
(0%), mild (0.1% to 9.9%), moderate (10% to
19.9%), and severe ($20%).
Outcome measures. The primary outcome measure
of cardiac death was available for 6,037 patients from3 centers and the secondary outcome of all-cause
mortality was available for all 7,061 patients (4 cen-
ters). Trained study coordinators, who were super-
vised by the site clinical investigators, performed
the determination of mortality status. Follow-up
was determined using scripted telephone interviews
and a review of electronic medical records. For pa-
tients who died, source documents (i.e., patient’s
medical record, verbal conﬁrmation by the patient’s
primary care physician, or review of death certiﬁ-
cates) were used for conﬁrmation. At all U.S. centers,
the National Death Index was applied for follow-up
and conﬁrmatory purposes.
Table 2. Rates of Cardiac Death (n [ 6,037) and All-Cause Mortality
(N [ 7,061)
Body Mass
Index, kg/m2 n
Cardiac
Death, n (%)
Annual Event
Rate, %
All 6,037 169 (2.8) 1.18
<25.0 1,303 46 (3.5) 1.55
25.0–29.9 2,047 61 (3.0) 1.10
$30.0 2,687 62 (2.3) 1.05
p Value 0.072
All-Cause
Mortality, n (%)
All 7,061 570 (8.1) 3.14
<25.0 1,650 208 (12.6) 5.31
25.0–29.9 2,411 190 (7.9) 2.84
$30.0 3,000 172 (5.7) 2.19
p Value <0.001
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281Statistical analysis. Statistical analyses were per-
formed using SAS (version 9.3, SAS Institute Inc.,
Cary, North Carolina) and SPSS (version 21.0, IBM,
Armonk, New York). Statistical signiﬁcance was
deﬁned as p < 0.05. Continuous variables were pre-
sented as mean  SD or median (interquartile range
[IQR]), and categorical variables were presented as
frequencies with percentages. The 2-sidedWilcoxon
rank sum test was used to compare continuous vari-
ables and chi-square test was used for categorical
variables.
Prognostic value of MPI was assessed for both
univariable and multivariable associations with car-
diac or all-cause death. Because noncardiac death
competes with cardiac death for mortality, a
competing risks analysis was performed for cardiac
death with noncardiac death. Cumulative incidence
function was used in estimating the probability of
cardiac death. For unadjusted comparisons of event
rates, a test proposed by Gray (16) was used for
the competing risk analysis of cardiac death and a
log-rank test was used for the all-cause death. Any
variables with a p value <0.10 in a univariable
analysis was included in a subsequent multivariable
models. For cardiac death, the subdistribution
hazard model proposed by Fine and Gray (17) was
used to assess the independent prognostic value of
MPI by adjusting for baseline clinical characteris-
tics. For all-cause death, the Cox proportional
hazard model was used. Model overﬁtting was
considered and the proportional hazards assumption
was met. The incremental prognostic value of the
model with MPI was evaluated by a signiﬁcant in-
crease in the global chi-square value and compared
by the global model ﬁt using the likelihood ratio
tests. The discrimination ability of the model
including clinical predictors and MPI to predict
cardiac or all-cause death was measured by the
C-index of Harrell and compared in different BMI
categories (18). The improvement of reclassiﬁca-
tion using the MPI was also assessed by calculating
the categorical free net reclassiﬁcation improve-
ment (19).
RESULTS
A total of 6,037 patients (mean age: 62.4  12.9
years, female: 48.1%) were followed for cardiac
death with a median follow-up of 2.2 years with an
IQR of 1.3 to 3.4 years (Table 1). Mean BMI was
30.5  7.4 kg/m2 and 1,303 patients (21.6%) were
classiﬁed as normal, 2,047 (33.9%) as overweight,
and 2,687 (44.5%) as obese. Of the 2,687 obese
patients, 1,343 (50.0%) were moderately obese and1,344 (50.0%) were severely obese. In our study
cohort, BMI was inversely related to age, and the
prevalence of many cardiac risk factors and symp-
toms increased with BMI severity. The prevalence
of normal MPI decreased with BMI (Table 1).
Similar ﬁndings were observed in the all-cause
mortality cohort (Online Table 1).
Cardiac death and all-cause mortality. Cardiac death
occurred in 169 (2.8%) patients, and all-cause death
occurred in 570 patients (8.1%), respectively
(Table 2). The annualized rate of cardiac death was
1.2% and all-cause mortality was 3.1%. There was a
trend toward cardiac death being inversely rated
to BMI (p ¼ 0.072), whereas a statistically signiﬁ-
cant result was observed for all-cause mortality
(p < 0.001) (Table 2).
Univariable analysis. Clinical parameters (age, sex,
symptoms, cardiac risk factors, history of revascular-
ization, and BMI) and PET MPI results (SSS,
summed rest score, and SDS) were signiﬁcant
predictors of cardiac death and all-cause mortality
(Table 3).
Stress perfusion defect and cardiac death and
all-cause mortality. The clinical predictors identi-
ﬁed in the univariable analysis were used to deter-
mine the incremental value of PET MPI measures
(Table 3). The models of cardiac death controlling
for the competing risk of noncardiac death showed
that SSS category had incremental prognostic value
to clinical variables including BMI. Worsening SSS
category was associated with increased rates of car-
diac death in all BMI categories (Fig. 1). Mild,
moderate, and severe SSS was associated with
greater hazard ratio (per category increase in SSS)
Table 3. Univariable Analysis of Clinical Characteristics for Cardiac Death and All-Cause Death
Cardiac
Death
(n [ 169)
No Cardiac
Death
(n [ 5,868)
Hazard
Ratio
(95% CI) p Value
All-Cause
Death
(n [ 570)
No Death
(n [ 6,491)
Hazard
Ratio
(95% CI) p Value
Age, per yr 71.5  11.2 62.1  12.8 1.07 (1.05–1.08) <0.001 71.3  11.4 62.7  13.0 1.06 (1.05–1.07) <0.001
Female 54 (32.0) 2,850 (48.6) 0.52 (0.37–0.71) <0.001 226 (39.6) 3,122 (48.1) 0.74 (0.63–0.88) 0.001
Cardiac risk factors
Smoker 47 (27.8) 1,388 (23.7) 1.40 (1.00–1.95) 0.048 111 (19.5) 1,415 (21.8) 0.98 (0.80–1.21) 0.085
Hypertension 121 (71.6) 3,883 (66.2) 1.38 (0.99–1.92) 0.059 429 (75.3) 4,363 (67.2) 1.61 (1.33–1.95) <0.001
Dyslipidemia 100 (59.2) 3,763 (64.1) 0.82 (0.61–1.12) 0.211 312 (54.7) 4,197 (64.7) 0.68 (0.57–0.80) <0.001
Diabetes 78 (46.2) 1,541 (26.3) 2.54 (1.87–3.44) <0.001 232 (40.7) 1,692 (26.1) 2.06 (1.74–2.43) <0.001
Chest pain or
dyspnea
89 (52.7) 3,689 (62.9) 0.63 (0.46–0.85) 0.002 323 (56.7) 4,226 (65.1) 0.68 (0.57–0.80) <0.001
History of CAD/
revascularization
72 (42.6) 1,525 (26.0) 2.27 (1.67–3.08) <0.001 194 (34.0) 1,701 (26.2) 1.55 (1.30–1.85) <0.001
LVEF* 38.1  18.6 57.6  14.1 0.93 (0.91–0.95) <0.001 51.7  18.9 60.7  15.1 0.97 (0.96–0.97) <0.001
BMI, kg/m2 0.80 (0.66–0.97) 0.022 0.65 (0.59–0.72) <0.001
<25.0 46 (27.2) 1,257 (21.4) 208 (36.5) 1,442 (22.2)
25.0–29.9 61 (36.1) 1,986 (33.8) 190 (33.3) 2,221 (34.2)
$30.0 62 (36.7) 2,625 (44.7) 172 (30.2) 2,828 (43.6)
PET parameters
SSS 2.27 (1.99–2.58) <0.001 1.60 (1.48–1.72) <0.001
Normal 21 (12.4) 2,500 (42.6) 160 (28.1) 2,949 (45.4)
Mild 60 (35.5) 2,341 (39.9) 203 (35.6) 2,401 (37.0)
Moderate 34 (20.1) 527 (9.0) 88 (15.4) 600 (9.2)
Severe 54 (32.0) 500 (8.5) 119 (20.9) 541 (8.3)
SRS 2.28 (2.00–2.59) <0.001 1.63 (1.49–1.77) <0.001
Normal 36 (21.3) 3,251 (55.4) 233 (40.9) 3,811 (58.7)
Mild 77 (45.6) 2,163 (36.9) 221 (38.8) 2,187 (33.7)
Moderate 32 (18.9) 240 (4.1) 58 (10.2) 274 (4.2)
Severe 24 (14.2) 214 (3.6) 58 (10.2) 219 (3.4)
SDS 1.55 (1.34–1.79) <0.001 1.34 (1.24–1.45) <0.001
Normal 70 (41.4) 3,669 (62.5) 278 (48.8) 4,109 (63.3)
Mild 7 (4.1) 252 (4.3) 19 (3.3) 240 (3.7)
Moderate 77 (45.6) 1,754 (29.9) 239 (41.9) 1,933 (29.8)
Severe 15 (8.9) 193 (3.3) 34 (6.0) 209 (3.2)
Values are mean  SD or n (%) unless otherwise indicated. *LVEF measure was available for 2,101 patients for cardiac death population (death: n ¼ 54) and 3,117 patients for all-cause death
population (death: n ¼ 257).
CI ¼ conﬁdence interval; other abbreviations as in Table 1.
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282for cardiac death and was incremental to clinical
predictors and BMI (Table 4). The same pattern
was observed with all-cause mortality (Online
Table 2).
The ability of the model (clinical predictors and
SSS) to predict cardiac or all-cause death was mea-
sured by the C-index of Harrell in each of the BMI
categories. C-statistics for cardiac death were similar
for each BMI category: normal ¼ 0.45 (95% conﬁ-
dence interval [CI]: 0.1 to 0.74); overweight ¼ 0.53(95% CI: 0.28 to 0.78); and obese ¼ 0.54 (95% CI:
0.28 to 0.78) (Table 5). The same observation
was made for all-cause mortality (Table 5).
The addition of PET MPI resulted in a category-
free net risk reclassiﬁcation improvement (NRI) of
0.46 (95%CI: 0.31 to 0.61) for cardiac death and 0.20
(95% CI: 0.11 to 0.28) for all-cause mortality. These
values were similar in moderate and severely obese
patients for cardiac death (NRI: 0.44 [95%CI: 0.12 to
0.76] and 0.63 [95% CI: 0.27 to 0.98], respectively)
AB
C
Figure 1. Cumulative Incidence Curves for Normal BMI,
Overweight, and Obese Patients
Comparisons of cumulative incidence of cardiac death according
to normal (blue), mildly (green), moderately (pink), and severely
(black dotted line) abnormal positron emission tomography
summed stress score in normal body mass index (BMI) (A),
overweight (B), and obese (C) patients (p < 0.01 for all).
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283and all-cause death (NRI: 0.20 [95%CI: 0.00 to 0.41]
and 0.28 [95% CI: 0.06 to 0.51], respectively).
PET MPI and annualized all-cause mortality and
cardiac death. A normal PET MPI conferred an
excellent prognosis (annual cardiac death) in normal
(0.38%), overweight (0.43%), and obese (0.15%)
patients. As well, both moderately and severe
obese patients with a normal PET MPI hadexcellent prognosis (0.20% and 0.10%, respectively)
(Table 6). As expected, patients with a severely
abnormal PET MPI fared worse (Table 6). Similar
results were observed with all-cause mortality
(Online Table 3).
Severity of ischemia, prior MI, and left ventricular
ejection fraction. The severity of ischemia (SDS) and
prior myocardial infarction (MI) had incremental
prognostic value over clinical variables, but both lost
their incremental value when SSS was added to the
multivariable model. This may be explained by the
fact that SSS is a measure of both ischemia (SDS)
and scar (prior MI). A subanalysis was performed
for all-cause mortality in the 3,117 patients with
left ventricular ejection fraction data. SSS (per cate-
gories) was incremental to clinical measures, prior
MI, BMI, and left ventricular ejection fraction
(hazard ratio: 1.17 [95% CI: 1.02 to 1.25]). However,
we were underpowered to detect the incremental
value of each SSS category.
D I SCUSS ION
Using a large multicenter PET registry, we
demonstrate that Rb-82 PETMPI has independent
and incremental prognostic value that is preserved in
patients who are overweight and obese. This is
especially relevant because obesity is a growing
pandemic and the diagnosis and risk stratiﬁcation of
obese patients can be challenging (1).
Accuracy of PET MPI in the obese population. PET’s
superior diagnostic accuracy and improved speci-
ﬁcity can be attributed to its better spatial resolution,
coincidence detection, and accurate attenuation
correction. Such advantages may be particularly
relevant in the increasingly obese population, which
is typically vulnerable to soft tissue attenuation
artifact and has poor acoustic echocardiogram
windows (20,21).
The accuracy of PET in obese patients has been
previously studied, but it could not be determined
in our study cohort. Notwithstanding, the results of
our analysis suggest that PET has prognostic value
and the low event rate in patients with normal PET
reassures us that we are unlikely to be missing
prognostically important CAD.
Rb-82 PET has been compared with single-
photon emission computed tomography (SPECT)
(without attenuation correction [AC]) and showed
that it has superior diagnostic accuracy (6–9). In
patients with a BMI of #30 kg/m2, the accuracy
by SPECT versus PET was 70% versus 87%, and
in obese patients, the accuracy was 67% versus
85%, respectively (6). Furthermore, they showed
Table 4. Competing Risk Models of Stress Perfusion Defect and Cardiac Death
Models Clinical Factors
Hazard
Ratios
(95% CI) p Value
Global
Chi-Square
Value
Clinical variables 196.43
Age 1.07 (1.06–1.09) <0.001
Female 0.55 (0.39–0.77) <0.001
Smoker 1.77 (1.26–2.49) 0.001
Hypertension 1.00 (0.71–1.40) 0.977
Diabetes 2.26 (1.65–3.10) <0.001
Angina or dyspnea 0.68 (0.50–0.93) 0.017
Prior revascularization 1.38 (0.98–1.93) 0.065
Clinical þ BMI 199.23
Age 1.07 (1.05–1.09) <0.001
Female 0.54 (0.39–0.76) <0.001
Smoker 1.76 (1.25–2.47) 0.001
Hypertension 1.01 (0.72–1.42) 0.967
Diabetes 2.32 (1.67–3.22) <0.001
Angina or dyspnea 0.69 (0.50–0.95) 0.021
Prior revascularization 1.36 (0.97–1.92) 0.077
BMI <25.0 kg/m2 1.0 d
BMI 25.0–29.9 kg/m2 0.81 (0.55–1.19) 0.278
BMI $30 kg/m2 0.83 (0.55–1.24) 0.352
Clinical þ BMI þ SSS 280.15
Age 1.06 (1.05–1.08) <0.001
Female 0.69 (0.49–0.98) 0.036
Smoker 1.69 (1.20–2.36) 0.002
Hypertension 1.03 (0.72–1.46) 0.886
Diabetes 2.02 (1.45–2.81) <0.001
Angina or dyspnea 0.73 (0.53–1.00) 0.049
Prior revascularization 1.01 (0.72–1.42) 0.948
BMI <25.0 kg/m2 1.0 d
BMI 25.0–29.9 kg/m2 0.77 (0.52–1.15) 0.205
BMI $30 kg/m2 0.78 (0.52–1.18) 0.238
SSS normal 1.0 d
SSS mild 2.41 (1.45–4.01) <0.001
SSS moderate 4.63 (2.59–8.28) <0.001
SSS severe 7.57 (4.39–13.06) <0.001
Abbreviations as in Tables 1 and 3.
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scans compared with 62% of SPECT studies.
With the adoption of iterative reconstruction,
SPECT þ AC is feasible, thus potentially im-
proving its diagnostic accuracy and prognostic value
in the obese population. Although a direct com-
parison of PET to contemporary SPECT þ AC has
been performed in a small cohort, the incremental
prognostic value of PET to SPECT þ AC isunknown (22). Thus, the results of our study sug-
gest that PET is a reasonable alternative in centers
without direct access to SPECT þ AC.
Prognosis of PET MPI. With improved diagnostic
accuracy, it is expected that Rb-82 PET would also
have prognostic value. The prognostic value of PET
has been previously demonstrated in multiple
single-center studies (7,9,11). Only recently, our
large multicenter registry, of which the current
Table 5. C-statistics of PET MPI for All-Cause Mortality and
Cardiac Death
C-Statistics (95% CI)
Cardiac death
BMI <25.0 0.45 (0.17–0.74)
BMI 25.0–29.9 0.53 (0.28–0.78)
BMI $30.0 0.54 (0.28–0.78)
All-cause mortality
BMI <25.0 0.65 (0.35–0.91)
BMI 25.0–29.9 0.62 (0.36–0.85)
BMI $30.0 0.61 (0.35–0.84)
MPI ¼ myocardial perfusion imaging; PET ¼ positron emission tomography;
other abbreviations as in Tables 1 and 3.
Table 6. Severity of Stress Perfusion Defect and
Cardiac Death (n [ 6,037)
n
Cardiac
Death,
n (%)
Annual
Event
Rate, %
BMI <25.0
Normal 656 7 (1.1) 0.38
Mild 408 18 (4.4) 2.37
Moderate 120 10 (8.3) 2.77
Severe 119 11 (9.2) 3.96
p Value <0.001
BMI 25.0–29.9
Normal 857 8 (0.9) 0.43
Mild 785 17 (2.2) 0.64
Moderate 184 12 (6.5) 2.15
Severe 221 24 (10.9) 4.51
p Value <0.001
BMI $30.0
Normal 1,008 6 (0.6) 0.15
Mild 1,208 25 (2.1) 1.01
Moderate 257 12 (4.7) 2.15
Severe 214 19 (8.9) 4.28
p Value <0.001
BMI 30.0–34.9
Normal 503 4 (0.8) 0.20
Mild 582 15 (2.6) 1.21
Moderate 139 8 (5.8) 2.81
Severe 119 9 (7.6) 3.76
p Value <0.001
BMI $35.0
Normal 505 2 (0.4) 0.10
Mild 626 10 (1.6) 0.80
Moderate 118 4 (3.4) 1.29
Severe 95 10 (10.5) 4.83
p Value <0.001
Abbreviation as in Table 1.
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285report is a subanalysis, has conﬁrmed the prognostic
value of Rb-82 PET previously observed in the
single-center studies (8). Dorbala et al. (8) demon-
strated that Rb-82 PET MPI perfusion severity
predicted all-cause mortality and cardiac death,
which was incremental to clinical predictors.
Prognosis of MPI in obese patients. Though the
prognostic value of SPECT in obese patients has
been previously studied (23–26), there is limited
data supporting the prognostic value of PET in
obese patients. A small single-center study sug-
gested that the prognostic value of Rb-82 PET is
preserved in a small obese cohort (9). However, data
supporting the prognostic value of Rb-82 PET in a
large multicenter obese population is limited. Our
study conﬁrms that the C-statistics were similar
across the different BMI categories and were pre-
served in the severely obese. Equally important, a
normal Rb-82 PET MPI portended excellent
prognosis with similarly very low event rates irre-
spective of BMI.
Given the advantages of Rb-82 PET and the
prognostic value of coronary ﬂow reserve, it would
be expected that coronary ﬂow reserve would also
have prognostic value in the obese patients.
Whether Rb-82 and coronary ﬂow reserve offer
superior prognostic information over existing
modalities remains to be determined.
Obesity paradox. The inverse relationship between
BMI and cardiac death has been referred to as the
“obesity paradox” and has previously been observed
by several groups (27–29). It is accepted that age is a
strong predictor of outcome. Although our analysis
adjusted for age, the fact that age was inversely
related to BMI may partly account the observed
paradox in the larger BMI patients. The observation
of the obesity paradox could also indicate the pres-
ence of referral bias and could be explained by thefact that obese patients may have lower exercise
tolerance or higher prevalence of exertional symp-
toms. Similarly, physicians may have a lower
threshold to investigate patients with a higher BMI.
The inverse relationship of SSS and BMI would
also support the notion that the prevalence of CAD
or ischemia was lower in the obese population.
Study limitations. A cardiac risk factor history was
available, but missing variables (such as fasting lipid
proﬁles) precluded the use of the traditional risk
prediction engines such as Framingham Risk Score.
Other clinical variables such as ejection fraction were
not available from all centers and, therefore, were not
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286included in the multivariable analysis. However,
previous studies have shown that PET MPI has
incremental prognostic value over ejection fraction
assessment; thus, we would not anticipate that our
results would differ from previous studies. Clinical
variables such as study indication, family history,
lipid proﬁle, medication use, and prior testing were
unavailable and, hence, may hinder the generaliz-
ability of our results. Although the majority of
patients were consecutively enrolled at each partici-
pating center, 1 center enrolled consecutive patients
with gated PET undergoing vasodilator stress and
another’s pooled cohort was composed of consecutive
patients with normal PET. Because patient enrol-
ment was independent of BMI, we do not believe
that our results are signiﬁcantly biased.
Although the category-free net risk reclassiﬁca-
tion appeared to be equally robust in the subgroup
of moderate and severely obese patients, our study
may have been insufﬁciently powered for obese
BMI group comparisons.
At the time of PET imaging (prior to July 1,
2009), there was no uniformly accepted approach
for detection and resolution of misalignment
between CT transmission and PET emission data.
Therefore, this information is not available fromthe different centers. With the adoption of
methods to detect misalignment artifacts, one
might anticipate that the diagnostic and prognostic
value of PET would only improve (30).
Whether prognostic value of PET is superior to
other modalities in obese patients remains unan-
swered. Therefore, future studies should consider
comparing the diagnostic and prognostic value of
different noninvasive modalities in the obese pop-
ulation. Such information would be important to
reduce equivocal results, necessitating downstream
testing, thereby improving resource utilization and
minimizing healthcare costs.CONCLUS IONS
Rb-82 PET has incremental prognostic value in all
patients irrespective of BMI. In the obese population
where other modalities may have reduced diagnostic
accuracy, cardiac PET appears to be a promising
noninvasive modality with prognostic value.
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